- Home
- DNTH vs SVRA Comparison
DNTH vs SVRA Comparison
Compare DNTH & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- SVRA
- Stock Information
- Founded
- DNTH 2015
- SVRA 2007
- Country
- DNTH United States
- SVRA United States
- Employees
- DNTH N/A
- SVRA N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- SVRA Health Care
- Exchange
- DNTH Nasdaq
- SVRA Nasdaq
- Market Cap
- DNTH 657.0M
- SVRA 528.3M
- IPO Year
- DNTH N/A
- SVRA N/A
- Fundamental
- Price
- DNTH $17.39
- SVRA $2.28
- Analyst Decision
- DNTH Strong Buy
- SVRA Buy
- Analyst Count
- DNTH 8
- SVRA 7
- Target Price
- DNTH $53.00
- SVRA $7.57
- AVG Volume (30 Days)
- DNTH 255.5K
- SVRA 2.5M
- Earning Date
- DNTH 05-12-2025
- SVRA 05-13-2025
- Dividend Yield
- DNTH N/A
- SVRA N/A
- EPS Growth
- DNTH N/A
- SVRA N/A
- EPS
- DNTH N/A
- SVRA N/A
- Revenue
- DNTH $6,524,000.00
- SVRA N/A
- Revenue This Year
- DNTH N/A
- SVRA N/A
- Revenue Next Year
- DNTH N/A
- SVRA N/A
- P/E Ratio
- DNTH N/A
- SVRA N/A
- Revenue Growth
- DNTH 102.36
- SVRA N/A
- 52 Week Low
- DNTH $13.37
- SVRA $1.89
- 52 Week High
- DNTH $32.27
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- DNTH 35.86
- SVRA 36.20
- Support Level
- DNTH $17.40
- SVRA $1.89
- Resistance Level
- DNTH $18.45
- SVRA $3.18
- Average True Range (ATR)
- DNTH 1.21
- SVRA 0.21
- MACD
- DNTH -0.22
- SVRA -0.11
- Stochastic Oscillator
- DNTH 10.60
- SVRA 29.77
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.